Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis

Varma, Ankur; Sui, Dawen; Milton, Denái R.; Tang, Guilin; Saini, Neeraj; Hasan, Omar; Mukherjee, Akash; Joseph, Jacinth; Bashir, Qaiser; Rondón, Gabriela; Srour, Samer A.; Popat, Uday; Hosing, Chitra; Nieto, Yago; Kebriaei, Partow; Alousi, Amin M.; Mehta, Rohtesh S.; Khouri, Issa F.; Ahmed, H.; Iyer, Swaminathan P.; Weber, Donna M.; Thomas, Sheeba K.; Manasanch, Elisabet E.; Lee, Hans C.; Patel, Krina; Ciurea, Stefan O.; Shpall, Elizabeth J.; Orłowski, Robert Z.; Champlin, Richard E.; Qazilbash, Muzaffar H.

doi:10.1016/j.bbmt.2019.12.726

Cited by 26 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from the present study regarding bortezomib are consistent with above data, suggesting that population with 1q + may confer resistance to bortezomib. Varma's team performed propensity score-matched analysis to compare MM patients with 1q + with/without [20]. Varma's study indicated that ASCT improved the outcomes of 1q + with/without 1p-though this approach did not fully overcome the negative impact of this cytogenetic change.…”

Section: Discussionmentioning

confidence: 99%

“…Gain or amplification of CKS1B also frequently occurs with the deletion of CDKN2C, a suppressor gene, at chromosome 1p32.3 (1p-), resulting in increased proliferation of plasma cells due to deregulation of G1 to S transition [17]. 1p-was reported to portend poor prognosis as well [18][19][20]. Given previous studies have reported conflicting results [13,14,21], and the prognosis of this particular population remains unclear in the era of monoclonal antibodies, we sought to describe…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy

Cowan

et al. 2021

Ann Hematol

View full text Add to dashboard Cite

Chromosome 1q gain/amplification (1q +) has been reported to be associated with inferior outcomes in multiple myeloma (MM) patients. Big therapeutic advances have shifted the treatment landscape by introducing monoclonal antibodies. There is a relative lack of data on outcomes in patients harboring this alteration in the era of monoclonal antibodies. Baseline characteristics and therapy-related data from newly diagnosed MM patients harboring 1q + detected by fluorescence in situ hybridization (FISH) were collected in a single institution. Among 34 identified subjects, the presence of elevated LDH was found to be associated with shorter overall survival (OS), and increased bone marrow plasma cell percentage (≥ 60%) was associated with worse progression-free survival (PFS). 1q + copy number more than three was associated with both shorter OS and PFS. Additionally, the administration of lenalidomide was associated with superior OS. The use of autologous stem cell transplantation, bortezomib, or daratumumab, was found to have no prognostic benefits in our sample. Lenalidomide may be an optimal therapeutic choice for this population, and future larger studies are warranted to confirm this benefit and further investigate the role of monoclonal antibodies in this subpopulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy

Cowan

et al. 2021

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…Saini et al reported MM patients with t(11;14) had similar outcomes as those with normal cytogenetic and FISH studies in a propensity score–matched analysis 39 . Varma et al reported that MM patients with 1q + /1p–were at significantly increased risk of progression or death compared to the propensity score–matched comparison group 40 . In the present study, the propensity score was defined as the conditional probability of receiving ASCT in an isolation room with HEPA.…”

Section: Discussionmentioning

confidence: 99%

The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation

Tsai

Yeh

Hong

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) continues to be the standard treatment for transplant-eligible multiple myeloma (MM) patients. A portion of MM patients received ASCT in an isolation room with high-efficiency particulate air (HEPA) filtration. The effectiveness of the HEPA filtration on reducing treatment-related mortality (TRM) is controversial. We enrolled patients with newly diagnosed MM in Taiwan between 2000 and 2017. The primary endpoint of the study was TRM, which was defined as death within 100 days after ASCT. A total of 961 MM patients received ASCT. Of them, 480 patients (49.9%) received ASCT in an isolation room with HEPA filtration (HEPA group). The median overall survival from ASCT was 7.52 years for the HEPA group and 5.88 years for the remaining patients (non-HEPA group) (p = 0.370). The 100-day mortality rate was 1.5% and 1.0% for the HEPA and non-HEPA groups, respectively. In the multivariate analysis, the 100-day mortality had no difference between the HEPA and non-HEPA groups (adjusted hazard ratio 1.65, 95% CI 0.52–5.23). The median cost for ASCT inpatient care was $13,777.6 and $6527.6 for the HEPA and non-HEPA groups, respectively (p < 0.001). Although half of MM patients in Taiwan received ASCT in HEPA room, it didn’t affect 100-day mortality.

show abstract

“…Saini et al reported MM patients t (11;14) had similar outcomes as those with normal cytogenetic and FISH studies in a propensity score-matched analysis 40 . Varma et al reported that MM patients with 1q+/1p-were at signi cantly increased risk of progression or death compared to the propensity score-matched comparison group 41 . In the present study, the propensity score was de ned as the conditional probability of receiving ASCT in an isolation room with HEPA.…”

Section: Discussionmentioning

confidence: 99%

The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation: A Nationwide Population-Based Study

Tsai

et al. 2020

Preprint

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is encouraged for transplant-eligible multiple myeloma (MM) patients. A portion of MM patients received ASCT in an isolation room with high-efficiency particulate air (HEPA) filtration. The effectiveness of the HEPA filtration on reducing treatment-related mortality (TRM) is controversial. We enrolled patients with newly diagnosed MM in Taiwan between 2000 and 2017. The primary endpoint of the study was TRM, which was defined as death within 100 days after ASCT. A total of 961 MM patients received ASCT. Of them, 480 patients (49.9%) received ASCT in an isolation room with HEPA filtration (HEPA group). The median overall survival from ASCT was 7.52 years for the HEPA group and 5.88 years for the remaining patients (non-HEPA group) (p = 0.370). The 100-day mortality rate was 1.5% and 1.0% for the HEPA and non-HEPA groups, respectively. In the multivariate analysis, the 100-day mortality had no difference between the HEPA and non-HEPA groups (adjusted hazard ratio 1.65, 95% CI 0.52–5.23). The median cost for ASCT inpatient care was $13777.6 and $6527.6 for the HEPA and non-HEPA groups, respectively (p < 0.001). Although half of MM patients in Taiwan received ASCT in HEPA room, it didn’t affect 100-day mortality.

show abstract

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis

Cited by 26 publications

References 37 publications

Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy

Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy

The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation

The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation: A Nationwide Population-Based Study

Contact Info

Product

Resources

About